Investigation of Oral Mucositis Incidence and Risk Factors in Patients Receiving Chemotherapy

Abstract

Abstract Purpose: Oral mucositis is a common complication of cancer treatment that may negatively impact the patient’s cancer treatment outcome. This study was done to determine the incidence of oral mucositis development and risk factors in patients receiving chemotherapy. Material and Methods: This prospective cohort study included 150 participants undergoing outpatient cancer chemotherapy. To determine the development of oral mucositis, the participants were evaluated for the first course of chemotherapy (day 0) and the next course of chemotherapy treatment (day 14). ‘Patient Information Form’ and the World Health Organization’ Mucositis Grading Scale’ were used to collect data for the study. Descriptive statistics, chi-squared test, and logistic regression were used to analyze the results. Results: According to oral mucosal assessment, incidence of oral mucositis was 27.3%. The mean onset and the mean recovery of oral mucositis were 4.16 ± 2.13 days and 8.72 ± 2.32 days. The most common oral problems were mouth dryness (53.3%), dental caries (44%), and decreased sense of taste (32%). In the oral mucosal assessment performed on the 14th day, 9 patients were found to be grade 1. Patients with a history of mucositis (OR = 5.76, Cl = 2.33–14.24, p = 0.00) showed a significantly higher incidence of oral mucositis. Conclusion: In this study, the incidence of oral mucositis and risk factors that may affect the development of oral mucositis in patients receiving chemotherapy were investigated. Mucositis history was found as a risk factor in oral mucositis development. Early recovery of oral mucositis after chemotherapy was observed. Therefore, patients should be followed up in the early period after chemotherapy.

Keywords

• oral mucositis,
• chemotheraphy,
• mucositis,
• risk factors,

References

1. 1. Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol 2015;27(3):159-164. https://doi.org/10.1097/CCO.0000000000000180
2. 2. Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin 2022;72:57–77. https://doi.org/10.3322/caac.21704
3. 3. Sonis ST. Precision medicine for risk prediction of oral complications of cancer therapy–The example of oral mucositis in patients receiving radiation therapy for cancers of the head and neck. Front Oral Health 2022;3-917860. https://doi.org/10.3389/froh.2022.917860.
4. 4. Curra M, Valente Soares Junior LA, Martins MD, da Silva Santos PS. Chemotherapy protocols and incidence of oral mucositis. An integrative review. Einstein (São Paulo) 2018;16(1):1-9. https://doi.org/10.1590/S1679-45082018RW4007
5. 5. Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE. Oral mucositis induced by anticancer therapies. Current Oral Health Reports 2015;2(4):202-211. https://doi.org/10.1007/s40496-015-0069-4
6. 6. Wardill HR, Sonis ST, Blijlevens NMA, Van Sebille YZA, Ciorba MA, Loeffen EAH, et al. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Supportive Care in Cancer 2020;28(11):5059-5073. https://doi.org/10.1007/s00520-020-05579-7
7. 7. Çavuşoğlu H. Evidenced based nursing in the management of oral mucositis: Review. Turkiye Klinikleri J Med Sci 2007;27(3):398-406.
8. 8. Shankar A, Roy S, Bhandari M, Rath GK, Biswas AS, Kanodia R, et al. Current trends in management of oral mucositis in cancer treatment. Asian Pac J Cancer Prev 2017;18(8):2019-2026. https://doi.org/10.22034/APJCP.2017.18.8.2019

9. 9. Cheng Fong KK, Lee V, Ho Li C, Goggins W, Thompson DR, Yuen HL, et al. Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy. Oral Oncol 2011;47(3):153-162. https://doi.org/10.1016/j.oraloncology.2010.11.019
10. 10. Yang TJ, Oh JH, Son CH, Apte A, Deasy JO, Wu A, et al. Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. Gastrointest Cancer Res 2013;6(5-6):129-136.
11. 11. Vokurka S, Bystricka E, Scudlova J, Mazur E, Visokaiova M, Vasilieva E, et al. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-L-PAM 200mg/m2 autologous hematopoietic stem cell transplantation. Eur J Oncol Nurs 2011;15(5):508-512. https://doi.org/10.1016/j.ejon.2011.01.006
12. 12. Alvariño-Martín C, Sarrión-Pérez MG. Prevention and treatment of oral mucositis in patients receiving chemotherapy. J Clin Exp Dent 2014;6(1),e74-e80. https://doi.org/10.4317/jced.51313
13. 13. Manzi NM, Silveira RCCP, Reis PED. Prophylaxis for mucositis induced by ambulatory chemotherapy: systematic review. J Adv Nurs 2016;72(4):735-746. https://doi.org/10.1111/jan.12867
14. 14. Eilers J, Million R. Clinical update: Prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs 2011;27(4):e1-e16. https://doi.org/10.1016/j.soncn.2011.08.001
15. 15. Eilers J, Harris D, Henry K, Johnson LA. Evidence based interventions for cancer treatment related mucositis: Putting evidence into practice. Clin J Oncol Nurs 2014;18(6):80-96. https://doi.org/10.1188/14.CJON.S3.80-96
16. 16. Salvador PT. Factors influencing the incidence and severity of oral mucositis in patients and undergoing autologous stem cell transplantation. Can Oncol Nurs J 2005;15(1):29-34. https://doi.org/10.5737/1181912x1512931.
17. 17. World Health Organization. World Health Organisation Hand-book for Reporting Results of Cancer Treatment. World Health Organization: Geneva, Switzerland, 1979.
18. 18. Shouval R, Kouniavski E, Fein J, Danylesko I, Shem-Tov N, Geva M, et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2019;103:402-409. https://doi.org/10.1111/ejh.13299
19. 19. Valeh M, Kargar M, Mansouri A, Kamranzadeh H, Gholami K, Heidari K, et al. Factors affecting the incidence and severity of oral mucositis following hematopoietic stem cell transplantation. Int J Hematol Oncol Stem Cell Res 2018;12(2):142-152.
20. 20. Kaytan E, Leblebicioğlu B, Coşar R, Taş Ş, Koyuncu H, Öngen B, et al. Efficacy of granulocyte macrophage colony-stimulating factor on oral mucositis. Turkish Journal of Oncology 2010;25(1):20-27.
21. 21. Wilberg P, Hjermstad MJ, Ottesen S, Herlofson BB. Chemotherapy-associated oral sequelae in patients with cancers outside the head and neck region. J Pain Symptom Manage 2014;48(6):1060-1069. https://doi.org/10.1016/j.jpainsymman.2014.02.009
22. 22. Çakmak S, Nural N. Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy. Int J Nurs Pract 2019;25(1):e12710. https://doi.org/10.1111/ijn.12710
23. 23. de Farias Gabriel A, Silveira FM, Curra M, Schuch LF, Wagner VP, Martins MAT, et al. Risk factors associated with the development of oral mucositis in pediatric oncology patients: Systematic review and meta‐analysis. Oral Dis 2022;28(4):1068-1084. https://doi.org/10.1111/odi.13863
24. 24. Ramirez-Amador V, Anaya-Saavedra G, Crespo-Solis E, Camacho EI, Gonzales-Ramirez I, Ponce-de-Leon S. Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy. Support Care Cancer 2010;18(5):639-646. https://doi.org/10.1007/s00520-009-0708-1
25. 25. Carreon-Burciaga RG, Castaneda-Castaneira E, GonzalezGonzalez R, Molina-Frechero N, Gaona E, Bologna-Molina R. Severity of oral mucositis in children following chemotherapy and radiotherapy and its implications at a single oncology centre in Durango State, Mexico. Int J Pediatr 2018;3252765– 3252765. https://doi.org/10.1155/2018/3252765
26. 26. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004;22(7):1268-1275. https://doi.org/10.1200/JCO.2004.05.147
27. 27. Vatca M, Lucas Jr JT, Laudadio J, D’Agostino RB, Waltonen JD, Sullivan CA, et al. Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol 2014;50(9):869-876. https://doi.org/10.1016/j.oraloncology.2014.06.010
28. 28. Valeh M, Kargar M, Mansouri A, Kamranzadeh H, Gholami K, Heidari K, et al. Factors affecting the incidence and severity of oral mucositis following hematopoietic stem cell transplantation. Int J Hematol Oncol Stem Cell Res 2018;12(2):142–152.
29. 29. De Francia S, Berchialla P, Armando T, Storto S, Allegra S, Sciannameo V, et al. Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities? Eur J Clin Pharmacol 2022;78:1029–1038. https://doi.org/10.1007/s00228-022-03298-y
30. 30. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, et al. Women experience greater toxicity with fluorouracil based chemotherapy for colorectal cancer. J Clin Oncol 2002;20(6):1491-1498. https://doi.org/10.1200/JCO.2002.20.6.1491
31. 31. Nishimura N, Nakano K, Ueda K, Kodaira M, Yamada S, Mishima Y, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer 2012;20(9):2053-2059. https://doi.org/10.1007/s00520-011-1314-6
32. 32. Moura CCG, Soares PBF, Vieira AE, Souza MAD, Dechichi P. Levels of immunoglobulin A1 in peri-implant fluid and saliva from patients with mucositis: a preliminary study. Braz Dent J 2013;24(4):380-384. https://doi.org/10.1590/0103-6440201302235
33. 33. Vokurka S, Steinerova K, Karas M, Koza V. Characteristics and risk factors of oral mucositis after allogeneic stem cell trans- plantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant 2009;44(9):601-605. https://doi.org/10.1038/bmt.2009.66